{"contentid": 488418, "importid": NaN, "name": "Diurnal completes \u00c2\u00a320 million placing to fund US Phase III clinical trial", "introduction": "UK endocrine diseases specialist Diurnal today said it has raised \u00c2\u00a320 million ($28 million) through a placing to fund the company\u00e2\u0080\u0099s pivotal Phase III trial for Efmody (hydrocortisone modified-release hard capsules), a drug formerly known as Chronocort, as a treatment for congenital adrenal hyperplasia in the US through to registration.", "content": "<p>UK endocrine diseases specialist Diurnal (AIM: DNL) today said it has raised &pound;20 million ($28 million) through a placing to fund the company&rsquo;s pivotal Phase III trial for Efmody (hydrocortisone modified-release hard capsules), a drug formerly known as Chronocort, as a treatment for congenital adrenal hyperplasia in the US through to registration.</p>\n<p>Diurnal, whose shares dipped 2.4% to 69.30 pence as trading neared close today, believes that the most expeditious route to commercialization of Efmody in the USA is to carry out the pivotal US Phase III study itself. In addition, it believes this will increase the future value of the program, as well as broadening the pool of potential commercialization partners.</p>\n<p>The company has had positive meetings with the US Food and Drug Administration and expects to receive formal agreement of the Special Protocol Assessment (SPA) for the US Phase III study during second-half 2021.</p>\n<p>In March 2021, Efmody received a positive opinion for approval from the European Medicines Agency with anticipated commercial launch in Europe in third quarter 2021.</p>\n<h2><strong>Funded through to profitability</strong></h2>\n<p>The company believes that it is now funded through to profitability for their late-stage cortisol replacement franchise based on current assumptions.</p>\n<p>Martin Whitaker, chief executive of Diurnal, commented: &ldquo;Having received a positive opinion for approval for Efmody from the EMA in March 2021 and, with our European launch expected in Q3 2021, we are pleased to announce that this fundraise will enable us to progress Efmody in the US, another key market for Diurnal. We have made excellent progress with our development plans for a pivotal Phase III clinical trial in the US for Efmody and, with the proposed new funds, we expect to initiate the study during H2 2021. In addition, successful completion of the fundraise will allow us to continue to support the development of our earlier stage pipeline, and is expected to ensure our late-stage cortisol replacement franchise is funded through to profitability.&rdquo;</p>", "date": "2021-04-21 16:22:00", "meta_title": "Diurnal completes \u00c2\u00a320 million placing to fund US Phase III clinical tr", "meta_keywords": "Diurnal, Placing, Funding, Efmody, Chronocort, Phase III, Hyperplasia, Adrenal", "meta_description": "Diurnal completes \u00c2\u00a320 million placing to fund US Phase III clinical trial", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-21 16:19:24", "updated": "2021-04-21 16:29:09", "access": NaN, "url": "https://www.thepharmaletter.com/article/diurnal-completes-20-million-placing-to-fund-us-phase-iii-clinical-trial", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "diurnal_logo-_big.jpg", "image2id": "diurnal_logo_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Endocrinology", "topic_tag": "Business Financing, Research", "geography_tag": "UK, USA", "company_tag": "Diurnal", "drug_tag": "Chronocort, Efmody", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-21 16:22:00"}